FindTrial
Sign In

Comparative study of ropinirole and entacapone for the treatment of wearing-off in advanced Parkinson's disease patients

Comparative study of ropinirole and entacapone for the treatment of wearing-off in advanced Parkinson's disease patients - ROPENT trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000003601
Enrollment
30
Registered
2010-05-18
Start date
2010-05-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson&#39

Interventions

Increase dosage of ropinirole Addition of entacapone

Sponsors

Kansai Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Parkinson disease patients who are in stage I to IV (mHY) at the on period. 2. Taking levodopa (300mg/day) and ropinirole (3-6mg/day) for 4+ weeks at the fixed dosage and experienced wearing off phenomenon.

Exclusion criteria

Exclusion criteria: 1. Severe peak dose dyskinesia or severe biphasic dyskinesia 2. Severe physical condition other than parkinsonism 3. Symptomatic orthostatic hypotension 4. history of drug or alcohol abuse 5. women who are pregnant or breastfeeding 6. viral hepatitis patients 7. past medical history of allergic to the test drugs 8. taking antiepileptic drugs 9. etc

Design outcomes

Primary

MeasureTime frame
Improvement of wearing-off—

Countries

Japan

Contacts

Public ContactSatoshi Kaneko

Kansai Medical University Neurology

06-6992-1001

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026